C3 Glomerulopathy Clinical Trial
Official title:
An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of LNP023 in Subjects With C3 Glomerulopathy
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy
Status | Recruiting |
Enrollment | 94 |
Est. completion date | December 1, 2028 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have completed the treatment period of the CLNP023X2202 or CLNP023B12301 trial on study drug Exclusion Criteria: - Severe concurrent co-morbidities, e.g. advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), or any illness or medical condition that in the opinion of the investigator and sponsor is likely to prevent the patient from safely tolerating LNP023 or complying with the requirements of the study - Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to screening, or the presence of fever = 38oC (100.4oF) within 7 days prior to screening. - History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects - History of HIV or any other immunodeficiency disease |
Country | Name | City | State |
---|---|---|---|
Argentina | Novartis Investigative Site | Buenos Aires | |
Brazil | Novartis Investigative Site | São Paulo | SP |
China | Novartis Investigative Site | Beijing | |
China | Novartis Investigative Site | Shanghai | |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigative Site | Paris | |
Germany | Novartis Investigative Site | Erlangen | |
Germany | Novartis Investigative Site | Essen | |
Greece | Novartis Investigative Site | Heraklion Crete | |
Israel | Novartis Investigative Site | Petach Tikva | |
Israel | Novartis Investigative Site | Petach-Tikva | |
Italy | Novartis Investigative Site | Ranica | BG |
Italy | Novartis Investigative Site | Roma | RM |
Japan | Novartis Investigative Site | Asahikawa-city | Hokkaido |
Japan | Novartis Investigative Site | Nagoya | Aichi |
Japan | Novartis Investigative Site | Sapporo | Hokkaido |
Netherlands | Novartis Investigative Site | Leiden | Zuid-Holland |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Spain | Novartis Investigative Site | Madrid | |
Switzerland | Novartis Investigative Site | Bern | |
Turkey | Novartis Investigative Site | Ankara | |
United Kingdom | Novartis Investigative Site | London | |
United Kingdom | Novartis Investigative Site | Newcastle Upon Tyne | |
United States | Novartis Investigative Site | Iowa City | Iowa |
United States | Novartis Investigative Site | Lawrenceville | Georgia |
United States | Novartis Investigative Site | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Argentina, Brazil, China, France, Germany, Greece, Israel, Italy, Japan, Netherlands, Spain, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CLNP023X2202 Cohort A-native C3G: Number of participants who achieve the composite renal endpoint | A participant meets the requirements of the composite renal endpoint if they satisfy the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., = the lower limit of normal (LLN)). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as not meeting the endpoint. | 9-month visit | |
Primary | CLNP023X2202 Cohort B - kidney transplant and recurrent C3G: Change from baseline in the C3 Deposit Score | Change from baseline in the C3 Deposit Score (based on immunofluorescence microscopy) compared to baseline in the CLNP023X2202 study. | 6 - to 9- month visit | |
Primary | Number of AEs of special interest | Number of participants with AEs of special interest will be collected to evaluate the long-term safety and tolerability of iptacopan in participants with C3G | Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301 | |
Primary | Number of participants with study drug discontinuation due to an AE (or any safety issue) | Number of participants with study drug discontinuation due to an AE to evaluate the long-term safety and tolerability of iptacopan in participants with C3G | Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301 | |
Primary | Number of participants with abnormal clinically significant vital signs,ECGs, and safety laboratory measurements | Number of participants with abnormal clinically significant vital signs, ECGs, and safety laboratory measurements to evaluate the long-term safety and tolerability of iptacopan in participants with C3G | Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301 | |
Secondary | CLNP023X2202: Number of participants who achieve the 2-component composite renal endpoint | A participant is defined as achieving the composite renal endpoint if they meet the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR.
Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint. |
9-month visit | |
Secondary | CLNP023X2202: Change from baseline in log-transformed urine protein/creatinine ratio (UPCR) | Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine protein/creatinine ratio (UPCR) | 3 month visit, 9-month visit and up to 66 months | |
Secondary | CLNP023X2202: Change from baseline in log-transformed urine albumin/creatinine ratio (UACR) | Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine albumin/creatinine ratio (UACR) | 3 month visit, 9-month visit and up to 66 months | |
Secondary | CLNP023X2202: Change from baseline in serum creatinine concentration | Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in serum creatinine at 9 months visit compared to CLNP023X2202 baseline | 9-month visit and up to 66 months | |
Secondary | CLNP023X2202: Change from baseline in estimated glomerular filtration rate (eGFR) | Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in eGFR at 9 months visit compared to CLNP023X2202 baseline | 9-month visit and up to 66 months | |
Secondary | CLNP023X2202: Status of C3G disease progression | Describe the status of C3G disease progression based on glomerular histopathology in a renal biopsy at 6 to 9 months from entry to the study compared to those obtained prior to treatment in the CLNP023X2202 study | 6 to 9 month visit | |
Secondary | CLNP023X2202: Log-transformed ratio to baseline in serum C3 | Long-term effect of LNP023 on son C3 at the 9-month visit by evaluating the Log-transformed ratio to baseline in serum C3 | 9-month visit and up to 66 months | |
Secondary | CLNP023X2202: Number of participants who achieve the composite renal endpoint | A participant is defined as achieving the composite renal endpoint if they meet the following criteria at times >9 months in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., LLN). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint. | Up to 66 months | |
Secondary | CLNP023X2202: Plasma LNP023 concentration up to 12 months at trough | Measurement of LNP023 plasma concentration to evaluate the pharmacokinetics of iptacopan in participants with prolonged treatment | 3-months, 6-months, 9-months and 12-months visits | |
Secondary | CLNP023B12301: Change from baseline in log-transformed UPCR over time by treatment groups | Change from baseline in log-transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria | Up to 36 months | |
Secondary | CLNP023B12301: Change from Day 180 in log-transformed UPCR over time (placebo arm of study CLNP023B12301) | Change from Day 180 in study CLNP023B12301 in log transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria | Up to 36 months | |
Secondary | CLNP023B12301: Change from baseline in eGFR over time | Change from baseline in eGFR will be assessed to evaluate the long-term effect of iptacopan on eGFR | Up to 36 months | |
Secondary | CLNP023B12301: Change from Day 180 in study CLNP023B12301 in eGFR over time (placebo arm of study CLNP023B12301) | Change in eGFR over time will be assessed to evaluate the long-term effect of iptacopan on eGFR | Up to 36 months | |
Secondary | CLNP023B12301: Number of participants who achieve a 2-component composite renal endpoint | A participant is defined as meeting the requirements of the composite renal endpoint if they satisfy the eGFR (a stable or improved eGFR, i.e., =15% reduction in eGFR compared to the baseline visit) and UPCR (=50% reduction in UPCR compared to the baseline visit) criteria assessed at a visit. The rate will be evaluated over time. | Up to 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04183101 -
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
|
Phase 2 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Not yet recruiting |
NCT05647811 -
Study of NM8074 in Adult C3 Glomerulopathy Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05067127 -
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Active, not recruiting |
NCT05809531 -
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Recruiting |
NCT06209736 -
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
|
Phase 2 | |
Terminated |
NCT03459443 -
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
|
Phase 2 | |
Completed |
NCT03369236 -
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
|
Phase 2 | |
Active, not recruiting |
NCT04572854 -
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
|
Phase 2 | |
Recruiting |
NCT02682407 -
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
|
Phase 2 | |
Recruiting |
NCT05083364 -
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
|
Phase 1 | |
Completed |
NCT03723512 -
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
|
N/A | |
Completed |
NCT03124368 -
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
|
Phase 2 | |
Available |
NCT04729062 -
C3G/Primary IC-MPGN EAP
|